Results 51 to 60 of about 2,004 (157)

Clinical efficacy and safety of switching from eculizumab to ravulizumab in adult patients with aHUS– real-world data

BMC Nephrology
Background The complement factor 5 (C5)-inhibitor eculizumab has been established as standard-of-care for the treatment of atypical hemolytic uremic syndrome (aHUS).
Kristina Schönfelder, Lucas Kühne, Lena Schulte-Kemna, Jessica Kaufeld, Hana Rohn, Andreas Kribben, Bernd Schröppel, Paul T. Brinkkötter, Anja Gäckler   +8 more
doaj   +1 more source

Porcine kidney xenotransplantation: From primate models to clinical reality

Animal Models and Experimental Medicine, Volume 9, Issue 6, Page 1142-1166, June 2026.
In the face of a critical shortage of human donor kidneys for end‐stage renal disease patients, porcine kidney xenotransplantation has emerged as a viable solution. This field has navigated major hurdles, including immune rejection, physiological incompatibilities, potential biomechanical differences and the risk of cross‐species infection. To overcome
Zihang Guo, Ling Zhang, Shoulong Deng, Chuan Qin   +3 more
wiley   +1 more source

Long-term effectiveness and safety of ravulizumab in paroxysmal nocturnal hemoglobinuria: a plain language summary

Journal of Comparative Effectiveness Research
What is this summary about? Paroxysmal nocturnal hemoglobinuria (PNH) is a rare disease where red blood cells break apart because they lack certain protective proteins.
Celso Arrais, Natalia Carnelutto, Jheremy Reyes   +2 more
doaj   +1 more source

Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti‐C5 therapy

HemaSphere, Volume 10, Issue 6, June 2026.
Abstract Patients with paroxysmal nocturnal hemoglobinuria (PNH) on anti‐C5 often experience extravascular hemolysis with anemia. Iptacopan, the first oral proximal complement inhibitor targeting factor B, has shown efficacy and safety in PNH patients. APPULSE‐PNH (NCT05630001), a phase 3b, single‑arm, open‐label trial, enrolled adult patients with PNH
Austin Kulasekararaj, Flore S. de Fontbrune, Anna Gaya, Ilene Weitz, David J. Kuter, Bhumika J. Patel, David J. Araten, Abhay Singh, Jun H. Jang, Richard J. Kelly, Eros Di Bona, Michael Loschi, Vinod Pullarkat, Jörg Schubert, Rosario Notaro, Mustafa N. Yenerel, Joan Beckman, Nicolas Blin, Irina Murakhovskaya, Jens Panse, Eloy Roman, Alexander Röth, Hubert Schrezenmeier, Srinivas Tantravahi, Régis P. de Latour, Navin Mahajan, Luca Monaco, Tao Ding, Tomasz Lawniczek, Philippe Ferber, Marion Dahlke, Antonio M. Risitano   +31 more
wiley   +1 more source

Ravulizumab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Network Meta-analysis of Ravulizumab and Alternative Interventions for the Treatment of Neuromyelitis Optica Spectrum Disorder

Neurology and Therapy
Introduction Anti-aquaporin-4 antibody-positive (AQP4-Ab+) neuromyelitis optica spectrum disorder (NMOSD) is a complement-mediated autoimmune disease in which unpredictable and relapsing attacks on the central nervous system cause irreversible and ...
Stacey L. Clardy, Sean J. Pittock, Orhan Aktas, Jin Nakahara, Noriko Isobe, Diego Centonze, Sami Fam, Adrian Kielhorn, Jeffrey C. Yu, Jeroen Jansen, Ina Zhang   +10 more
doaj   +1 more source

Real-World Prevalence and Outcomes of Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with C5 Inhibitors in the US: A Retrospective Claims Database Analysis

Journal of Health Economics and Outcomes Research
# Background Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder with C5 inhibitors (C5i), eculizumab and ravulizumab, being part of current treatment options.
Srinivas K Tantravahi, Dominick Latremouille-Viau, Raj Desai, Soyon Lee, Jincy Paulose, Anumaxine Geevarghese, Annie Guérin, Shravanthi Seshasayee, Mohin Chanpura, Glorian Yen   +9 more
doaj   +1 more source

Ravulizumab and Efgartigimod in Myasthenia Gravis

Neurology Neuroimmunology & Neuroinflammation
Finanziert durch den Open-Access-Publikationsfonds der Universität Münster.
Frauke Stascheit, Carla Daiane Ferreira de Sousa, Annette Aigner, Malina Behrens, Christian W. Keller, Luisa Klotz, Sophie Lehnerer, Maike Stein, Meret Herdick, Paolo Doksani, Lea M. Gerischer, Sarah Hoffmann, Konstantinos Lazaridis, John Tzartos, Heinz Wiendl, Andreas Meisel, Jan D. Lünemann   +16 more
openaire   +4 more sources

Ravulizumab in adults and children with atypical hemolytic uremic syndrome: a plain language summary of three studies

Journal of Comparative Effectiveness Research
This summary gives an overview of three published articles that report the results of research studies of ravulizumab, an approved treatment for people with atypical hemolytic uremic syndrome (often shortened to aHUS).
Michal Nowicki, Nikoleta Printza
doaj   +1 more source

Ravulizumab

Reactions Weekly, 2022
openaire   +2 more sources